Manitoba is set to begin offering a single-dose immunization for RSV this fall. According to a provincial spokesperson, as of Oct. 1, Manitoba’s RSV Immunoprophylaxis Program for high-risk infants will start providing nirsevimab – a long-acting monoclonal antibody that lasts a full season. Currently, the program offers a multi-dose anti-body treatment. This change comes more than a year after Canada’s national advisory committee recommended the switch. RSV season generally runs from late fall to early spring, with most cases reported between December and March.